Construct Validity of PROMIS® Cognitive Function in Cancer Patients and Noncancer Controls

Objective: The Patient-Reported Outcomes Measurement Information System Cognitive Function-Concerns® (PROMIS®-CF-Concerns) assesses self-reported cognitive complaints. Construct validity data for the CF-Concerns are few. To add to the literature, an analysis of criterion validity for cognitive compl...

Full description

Saved in:
Bibliographic Details
Published in:Health psychology 2019-05, Vol.38 (5), p.351-358
Main Authors: Valentine, Thomas R, Weiss, David M, Jones, Jeffrey A, Andersen, Barbara L
Format: Article
Language:English
Subjects:
Adult
Aged
Anxiety
Cancer
Cognition - physiology
Cognitive ability
Cognitive functioning
Cognitive Impairment
Cognitive skills
Comorbidity
Complaints
Concerns
Construct Validity
Discriminant Validity
Emotions
Female
Fluency
Human
Humans
Leukemias
Male
Measurement
Mental depression
Middle Aged
Negative Emotions
Neoplasms
Neoplasms - epidemiology
Neuropsychological Assessment
Neuropsychological Tests - standards
Patient Reported Outcome Measures
Reproducibility of Results
Self report
Test Validity
Validation studies
Validity
Verbal Fluency
Verbal memory
Word association
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The Patient-Reported Outcomes Measurement Information System Cognitive Function-Concerns® (PROMIS®-CF-Concerns) assesses self-reported cognitive complaints. Construct validity data for the CF-Concerns are few. To add to the literature, an analysis of criterion validity for cognitive complaints (European Organisation for Research and Treatment of Cancer-Cognitive Functioning subscale [EORTC-CF]) and cognitive performance (neuropsychological tests of memory [NIH Toolbox Auditory Verbal Learning Test] and verbal fluency [Controlled Oral Word Association Test]) and discriminant validity (self-reports of negative emotions of anxiety, depression, negative mood) are provided. A two-group comparison design was used. Method: Forty-four patients with chronic lymphocytic leukemia (CLL) and 44 age- and gender-matched noncancer controls completed self-report measures and neuropsychological tests. Spearman's rank correlations (rs) and independent-samples t tests were used. Results: Regarding criterion validity, PROMIS®-CF-Concerns significantly correlated with the EORTC-CF (rs = 0.77, p < .001), although not with tests of memory (−0.19) or verbal fluency (0.16). As expected, patients with CLL performed lower than did controls on neuropsychological tests (ps < .05) yet did not differ from controls on PROMIS®-CF-Concerns. PROMIS®-CF-Concerns was reliably and significantly correlated with negative emotions, with rs ranges across measures of −0.42 to −0.69 for the CLL group and −0.53 to −0.78 for controls. Conclusions: PROMIS®-CF-Concerns exhibited high internal consistency. Criterion validity was evidenced for cognitive complaints though not for cognitive performance as assessed here. In summary, the analysis supports the criterion validity of PROMIS®-CF-Concerns for cognitive complaints. It also covaries with self-reports of co-occurring anxiety, depression, and negative mood.
ISSN:0278-6133
1930-7810
DOI:10.1037/hea0000693